Zai Lab Ltd (09688) announced its interim results for 2025, reporting total revenue of $216 million USD, representing a 15.35% year-over-year increase. Net loss amounted to $89.165 million USD, a 33.33% decrease compared to the same period last year, with loss per share of $0.08 USD.

Net product revenue increased by $27.5 million (or 15%) to $215 million USD, primarily driven by growth in sales of Weiwejia due to extended treatment duration and improved market penetration, increased sales of Niuzaile supported by expanded market coverage and penetration, and sales growth of Dingyoule, which has been available since the fourth quarter of 2024.

Research and development expenses decreased by $4.9 million (or 4%) to $111 million USD, mainly due to reduced personnel and clinical trial costs resulting from ongoing resource optimization and efficiency improvements, partially offset by increased licensing fees.